Ankylosing spondylitis: New criteria, new treatments

Bulletin of the NYU Hospital for Joint Diseases

Volumn 68, Issue 3, 2010, Pages 171-174

  Haroon, Nigil ^a   Inman, Robert D ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; CERTOLIZUMAB PEGOL; GOLIMUMAB; PLACEBO; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ANKYLOSING SPONDYLITIS; ARTICLE; AXIAL SPONDYLOARTHRITIS; BACKACHE; BONE RADIOGRAPHY; CHRONIC DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; FOOD AND DRUG ADMINISTRATION; HUMAN; INFLAMMATORY DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; REMISSION; RHEUMATOID ARTHRITIS; SACROILIITIS; SENSITIVITY AND SPECIFICITY; SPONDYLARTHRITIS; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT RESPONSE;

ANTI-INFLAMMATORY AGENTS; HUMANS; LOW BACK PAIN; PREDICTIVE VALUE OF TESTS; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 78449245426     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Wellcome Trust Case Control Consortium; Australo-Anglo-American Spondylitis Consortium (TASC), Burton PR, Clayton DG, Cardon LR, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet. 2007;Nov;39(11):1329-37.
2. Australo-Anglo-American Spondyloarthritis Consortium (TASC), Reveille JD, Sims AM, Danoy P, Evans DM, et al. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet. 2010 Feb;42(2):123-7; Epub 2010 Jan 10.
3. Haroon N, Inman RD. Endoplasmic reticulum aminopeptidases: biology and pathogenic potential. Nat Rev Rheumatol. 2010 Aug;6(8):461-7; Epub 2010 Jun 8.
4. Sieper J, van der Heijde D, Landewe R, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis. 2009 Jun;68(6):784-8; Epub 2009 Jan 15.
5. Rudwaleit M, Landewe R, van der Heijde D, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis. 2009; Jun;68(6):770-6.
6. Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009 Jun;68(6):777-83.
7. Calin A, Porta J, Fries JF, Schurman DJ. Clinical history as a screening test for ankylosing spondylitis. JAMA. 1977 Jun; 13;237(24):2613-4.
8. Rudwaleit M, Metter A, Listing J, et al. Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum. 2006 Feb;54(2):569-78.
9. Wordsworth BP, Mowat AG. A review of 100 patients with ankylosing spondylitis with particular reference to socio-economic effects. Br J Rheumatol. 1986 May;25(2):175-80.
10. Calin A, Elswood J, Rigg S, Skevington SM. Ankylosing spondylitis-an analytical review of 1500 patients: the changing pattern of disease. J Rheumatol. 1988 Aug;15(8):1234-8.
11. Bennett AN, McGonagle D, O'Connor P, et al. Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum. 2008 Nov;58(11):3413-8.
12. Haroon N, Inman RD. Infectious complications of biological therapy. Curr Opin Rheumatol. 2009 Jul;21(4):397-403.
13. Inman RD, Davis JC Jr, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;Nov;58(11):3402-12.
14. Song IH, Heldmann F, Rudwaleit M, et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum. 2010 May;62(5):1290-7.
15. Sieper J, Baraliakos X, Listing J, et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology (Oxford). 2005 Dec;44(12):1525-30.
16. Linde K, Witt CM, Streng A, et al. The impact of patient expectations on outcomes in four randomized controlled trials of acupuncture in patients with chronic pain. Pain. 2007 Apr;128(3):264-71.
17. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006 Jun 20;144(12):865-76.
18. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005 Sep 15;353(11):1114-23.
19. Olivieri I, D'Angelo S, Mennillo GA, et al. Abatacept in spondyloarthritis refractory to tumour necrosis factor alpha inhibition. Ann Rheum Dis. 2009 Jan;68(1):151-2.
20. Song IH, Heldmann F, Rudwaleit M, et al. Treatment of active ankylosing spondylitis with abatacept-an open label 24-week study. Ann Rheum Dis. 2010;69(Suppl 3):60.
21. Strand V, Mease P, Burmester GR, et al. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthritis Res Ther. 2009;11(6):R170.
22. Smolen J, Landewe RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis. 2009 Jun;68(6):797-804.
23. Feagan BG, Coteur G, Tan S, et al. Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease. Am J Gastroenterol. 2009;Aug;104(8):1976-83.